CBP-174

About Connect Biopharma

Connect Biopharma's mission is to develop best-in-class therapies for immune-mediated diseases with significant unmet need, focusing on chronic inflammatory conditions like atopic dermatitis, asthma, and inflammatory bowel disease. Its key achievement is advancing rademikibart (CBP-201) into global Phase 3 trials for atopic dermatitis, generating promising efficacy and safety data. The company's strategy involves capital-efficient, data-driven clinical development across major markets (US, China, EU) to create partnership and commercialization opportunities. With a public listing on NASDAQ, Connect aims to translate its clinical pipeline into validated treatments and strategic value.

Therapeutic Areas

Other Pruritus in Atopic Dermatitis Drugs